Kornimate/medical-research-clean huggingface dataset:
learning curve for robot-assisted gastrectomy in gastric cancer

Conditions: Stomach Neoplasms

Summary: the investigators prospectively collected the clinical data of da vinci robot-assisted radical gastrectomy patients conducted by the same group of physicians from october 2017 to october 2018. the learning curve of the surgery was analyzed with the moving average method and the cumulative sum analysis (cusum). the short-term efficacy was then validated by comparing the perioperative and pathologic outcomes of patients in the two stages of the learning curve.


Eligibility criteria:
inclusion criteria: * 1.patients were 18-90 years old * 2. patients with a documented diagnosis of gastric adenocarcinoma * 3. patients were scheduled to undergo minimally invasive gastric cancer surgery * 4.patients with no preoperative evidence of serosal invasion or extraperigastric lymph node metastasis on preoperative computed tomography scans, upper endoscopy, and endoscopic ultrasound exclusion criteria: * 1. patients with neoadjuvant treatment * 2. patients procedure concurrent with the gastrectomy * 3.patients with palliative surgery * 4. patients with the contraindications for general anesthesia * 5. patients were pregnant or mentally incompetent * 6. patients with serious systemic comorbidities, such as severe heart failure, respiratory failure, uncontrolled hypertension
early initiation of oral feeding versus traditional feeding post caesarean section

Conditions: Complication; Postoperative

Summary: early initiation of oral feeding, within 6-12 hours post-caesarean section, has been noticed to be well tolerated by patients and helps them recover fast. our study aimed to evaluate the tolerability, safety and benefits of early oral feeding post-caesarean section.

background: early initiation of oral feeding, within 6-12 hours post-caesarean section, has been noticed to be well tolerated by patients and helps them recover fast. however, the traditional method of waiting for 24 hours to commence oral feeding post-caesarean section is still being widely practiced due to the fear of post-operative ileus. though some studies have shown this fear to be unfounded, early initiation of oral feeding is not yet universally accepted. objectives: to evaluate the tolerability, safety and benefits of early oral feeding post-caesarean section. study design and setting: this was a randomized control trial (equivalence) carried out at alex ekwueme federal university teaching hospital abakaliki, nigeria. methods: three hundred and six eligible women, randomized into groups (a=early and b=traditional feeding group) were admitted into the post natal ward after elective or emergency caesarean section. women in group a were commenced on graded oral sips 6 hours post- caesarean section and subsequently soft diets from the 12th hour, after oral sips were well tolerated, while those in group b were commenced on the same regimen as in group a 24 hours post-caesarean section. main outcome measure: time of return of bowel sound, time of resuming normal diets, duration of hospital stay, and post-operative complications analysis: data obtained were analyzed using the computer software, ibm spss version 26. frequency tables were made and results tested for significance using the t-test for continuous variables and chi-square test for categorical variables. relative risk (rr) was also determined, with confidence interval set at 95% and the level of significance determined by p-value \< 0.05

Eligibility criteria:
inclusion criteria: * pregnant women included in this study were those booked for elective or emergency caesarean section under spinal anaesthesia, for various indications from antenatal clinic, antenatal ward, labour ward and obstetric emergency unit who met inclusion criteria and consented to the study. exclusion criteria: * women with prolonged obstructed labour. * women with immunosuppression or hiv/aids * women with eclampsia. * women with medical complications of pregnancy such as: * sickle cell anaemia, uncontrolled diabetes, uncontrolled hypertension. * women who received general anaesthesia * women with previous history of bowel surgery * women on drugs that can cause constipation * women with previous history of chronic constipation

Keywords: caesarean section post-operative feeding paralytic ileus
using pulse counter vigileo-flotrac system in transapical off-pump minimally invasive mitral valve repair

Conditions: Mitral Valve Prolapse

Summary: minimally invasive transapical off-pump chordae implantation includes features such as tachycardia, arrhythmia, hemorrhage, sudden hemodynamic changes caused by the device moving in the left ventricle and the atrium, for anesthetists. in this observational study, the investigators presented the investigators's hemodynamic recuperation and anesthesia experiences revealed by cardiac output measurement after transapical mitral valve repair.

in sakarya university educational research hospital, perioperative file records of 13 patients who underwent mitral valve repair using the neochord ds1000 system were retrospectively analyzed. in addition, hemodynamic measurements recorded with the vigileo flotrac invasive arterial cardiac output device were evaluated.

Eligibility criteria:
inclusion criteria: * all patients that surgical criteria for neochord implantation with transapical mini-thoracotomy are prolapsus or chordae rupture in posterior, anterior areas or in both leaflets were included. exclusion criteria: * exclusion criteria are active endocarditis, functional or ischemic mitral insufficiency (mi), excessive calcific valves, leaflet perforation, anemic dilatation and severe left ventricular dysfunction.

Keywords: mitral valve prolaps, chorda tendinea, cardiac output
rotator cuff augmentation with human dermal allograft versus bovine collagen xenograft patch: a randomized controlled trial

Conditions: Rotator Cuff Tears

Summary: randomized controlled trial comparing human dermal allograft with bovine collagen xenograft in rotator cuff repair.

randomized controlled trial comparing human dermal allograft with bovine collagen xenograft in rotator cuff repair. subjects will be randomized intraoperatively after confirmation of inclusion criteria. subjects will be followed-up at 3 weeks, 3 months, 6 months, 12 months and 24 months post-operatively. primary outcome is western ontario rotator cuff index (worc) at 12 months. additional outcomes include american shoulder and elbow surgeons questionnaire (ases), single numeric evaluation (sane) score, euroqol (5 domains) score (a quality of life score), and visual analogue scale, healing rate as determined by magnetic resonance imaging (mri) scan at 12 months post surgery. to determine the cost utility, data will be collected on the cumulative cost for the total episode of care up to 12 months post surgery inclusive of surgical costs, implant costs, outpatient costs, and medication costs. quality-adjusted life years (qalys) gained will be calculated using the mean total cost and the quality of life score (eq-5d) improvement from pre-operative to 12 months post surgery.

Eligibility criteria:
inclusion criteria: \>18 years - fully reparable full thickness rotator cuff tear whereby the treating surgeon feels a graft augment is needed to enhance healing exclusion criteria: * tears where only a partial repair is achieved * significant glenohumeral joint arthropathy (hamada grade 2 and above) * irreparable rotator cuff tears * patients unable or unwilling to consent or comply with study questionnaires * patients with upper limb neurological deficits affecting the ipsilateral limb * workers compensation cases * cases involving litigation
research on oral tolerability and product application/response of two oxalate products for dental patients with risk of dentinal hypersensitivity

Conditions: Dentinal Hypersensitivity

Summary: this study will assess the oral tolerability and immediate post-treatment safety of topical application for two marketed oxalate products as initial care in dental patients to treat or prevent tooth sensitivity pain that may be attributed to dentinal hypersensitivity.


Eligibility criteria:
inclusion criteria: * be at least 18 years of age * sign an informed consent form and be given a copy * be in good general health as determined by the investigator/designee * agree to not participate in any other oral care study for the duration of this study * agree to return for scheduled visits and follow all study procedures * have at least one tooth at risk for hypersensitivity. exclusion criteria: * any medical condition requiring pre-medication prior to dental procedures * any diseases or conditions that might interfere with the subject safely completing the study * inability to undergo study procedures * a history of kidney stones * have self-reported pregnancy or nursing * known allergies to the following ingredients; aqua, glycerin, cellulose gum, dipotassium oxalate, carbomer, sodium hydroxide, sodium benzoate, or potassium sorbate
neuromodulation of lidocaine cream effect on chronic pain patients

Conditions: Chronic Low Back Pain

Summary: chronic low back pain patients aged 21 to 60 needed for a research study of the effects of transcranial direct current stimulation (tdcs) on the analgesic effects of lidocaine cream as measured by functional magnetic resonance imaging (fmri). study will be conducted on nine separate days not requiring an overnight stay in the hospital.


Eligibility criteria:
inclusion criteria: * volunteers 21-60 years of age. * meets the classification criteria of chronic lbp (having low back pain for more than 6 months), as determined by the referring physician. * at least 4/10 clinical pain on the 11-point lbp vas (criteria recommended by dworkin et al.) * at least a 10th grade english-reading level; english can be a second language provided that the patients understand all questions used in the assessment measures. exclusion criteria: * specific causes of back pain (e.g., cancer, fractures, spinal stenosis, infections). * complicated back problems (e.g., prior back surgery, medicolegal issues). * the intent to undergo surgery during the time of involvement in the study. * history of cardiac, respiratory, or nervous system disease that, in the investigator's judgment, precludes participation in the study because of a heightened potential for adverse outcome. for example: asthma, claustrophobia, epilepsy or acute eczema under the electrodes. * presence of any contraindications to mri scanning. for example: cardiac pacemaker, metal implants, claustrophobia, pregnancy, cannot lie still in an fmri scanner. * history of medical or psychiatric illness. * history of substance / alcohol abuse or dependence.
emollient 'plus' vs urea 10% for mild-moderate atopic dermatitis

Conditions: Dermatitis, Atopic

Summary: the goal of this clinical trial is to evaluate the effectiveness and tolerability of an emollient aqua posae + microesyl compared to urea 10% in patients with mild-moderate atopic dermatitis the main question it aims to answer is: " to evaluate the effectiveness and tolerability of an emollient aqua posae + microesyl compared to urea 10% in patients with mild-moderate atopic dermatitis age 18 years and above". moisturizer application will be performed twice daily, 3 minutes after bathing, with a standardized dose using the finger tip unit (ftu) method.


Eligibility criteria:
inclusion criteria: * male or female aged ≥18 years * ad patients who meet the criteria for ad diagnosis according to the hanifin-rajka criteria. * patients with mild-moderate ad according to the scorad index. * patients who have ad lesions on the hands and/or feet. * patients with good general condition. * patients are willing to participate in the study and sign the informed consent. exclusion criteria: * pregnant and lactating patients. * patients with a history of allergies to ingredients contained in moisturizers * patients who clinically have other skin diseases such as psoriasis, seborrheic dermatitis, contact dermatitis or ad with secondary infections that can affect the scorad index parameters, skin hydration, skin ph and side effects on the skin area being assessed. * patients receiving topical or systemic immunomodulatory and/or immunosuppressant therapy. * patients receiving topical and/or systemic antibiotic therapy * patients receiving systemic antihistamine therapy (patients who require antihistamines during the study will be recorded on the observation sheet)

Keywords: atopic dermatitis skin barrier moisturizer bacterial lysate clinical efficacy
ctdna-directed post-hepatectomy chemotherapy for patients with resectable colorectal liver metastases

Conditions: Liver Metastases

Summary: to determine if the detection of ctdna after surgical resection of clm can stratify patients into high and low-risk cohorts for early disease recurrence in order to inform post-operative adjuvant therapy.

primary objective: • to assess 1-year recurrence-free survival rate following liver resection of clm with curative intent among ctdna-negative patients who receive risk-stratified postoperative chemotherapy secondary objectives: * to assess recurrence-free survival following liver resection of clm with curative intent among ctdna-positive patients * to assess overall survival following liver resection among ctdna-negative and ctdna-positive patients * to evaluate the proportion of ctdna-negative at 1-year post-resection * to compare survival of ctdna-negative patients undergoing ctdna-guided postoperative chemotherapy to historical controls * to evaluate proportion of patients in each arm who change chemotherapy in response to ctdna measurement * to delineate the pattern of disease recurrence * to assess ctdna sensitivity and specificity for predicting disease recurrence * to evaluate mdasi-gi during the course of postoperative therapy * to evaluate and correlate patient molecular subtypes and characterization of tumor biologic factors that are associated with ctdna detection * to evaluate surgery-related adverse events occurring up to 90 days after surgery, and chemo-related adverse events occurring up to 30 days after the last dose of chemotherapy outcome measures: primary: • recurrence-free survival at 1-year post-hepatectomy among ctdna-negative patients secondary: * recurrence-free survival at 1-year post-hepatectomy among ctdna-positive patients * overall survival (os) among ctdna-negative and ctdna-positive patients * ctdna-negativity at 1-year post-resection * proportion of patients in each group with chemotherapy regimen change in response to ctdna dynamics * pattern of disease recurrence (i.e., liver, systemic, salvageable vs. unsalvageable) * ctdna sensitivity/specificity for recurrent disease overall by timepoint * mdasi-gi at clinic visits during course of postoperative therapy * tumor radiologic, histologic, and molecular profiling and correlative characterization based upon ctdna detection * adverse events

Eligibility criteria:
inclusion criteria: * patients ≥18 years of age with clm undergoing elective hepatectomy with curative intent (primary colorectal primary cancer previously removed or being removed at time of hepatectomy) after preoperative chemotherapy (i.e., folfox/folfiri +/- bevacizumab or panitumumab/cetuximab) from 07/01/2021 - 12/31/2023 * must receive ≥ 4 cycles of preoperative chemotherapy exclusion criteria: * patients with primary colorectal tumor that will remain in situ * inability to undergo postoperative chemotherapy, or postoperative chemotherapy not planned a priori * unwilling/unable to undergo blood draws for ctdna, patient or provider-determined * other active malignancies requiring treatment * women who are pregnant
evaluation of efficacy, quality of life and cost effectiveness of short-course radiotherapy followed by capecitabine plus oxaliplatin chemotherapy and tme for high-risk rectal cancer (escort trial)

Conditions: Locally Advanced Rectal Cancer

Summary: multimodality treatment including surgery and radiotherapy is the current standard of care in locally advanced rectal cancer. most clinical trials comparing short course radiotherapy (scrt) with long course chemoradiotherapy(lcrt) did not find significant differences in oncological outcomes and short-term outcomes even though some debates. recently, stockholm iii trial comparing scrt plus delayed surgery with scrt plus immediate surgery and lcrt demonstrated no differences with respect to short-term outcomes such as complications, mortality, and acute toxicity. however, overall quality of life (qol) after curative treatment for rectal cancer is still major concern in both scrt and lcrt. furthermore, daily hospital visits for 5 weeks may be the cause of the increase of total medical cost due to indirect medical expense in patients with lcrt, especially in rural area. scrt plus chemotherapy followed by delayed surgery may have the possibility of reducing total hospital costs as well as increasing qol by proving non-inferiority in terms of perioperative outcomes. the present prospective single-arm phase 2 trial was designed to validate the efficacy, quality of life and cost effectiveness of preoperative short-course radiotherapy plus xelox chemotherapy followed by delayed surgery for high-risk rectal cancer patient based on magnetic resonance imaging.


Eligibility criteria:
inclusion criteria: 1. high-risk patients of rectal cancer on pretreatment mri using the following risk stratification system location of the lower part of the tumor is measured below less than 10 cm on the anal verge and lower part of the tumor is located below the lower limit of the peritoneal reflection. if there is more than one, classify as a high risk group positive crm threatening: 5mm ≦ extramural depth positive emvi. cn2: positive lateral pelvic ln metastasis 2. between 19 and 80 years of age; 3. satisfactory performance status: ecog≦2 4. american society of anesthesiologists (asa) physical status classification system class i\~iii 5. adequate hematologic function: white blood cell(wbc) counts≥4,000/mm3, neutrophils counts ≥ 1,500/mm3, platelet counts ≥ 100,000/µl, hemoglobin ≥ 9g/l; 6. adequate renal function: creatinine ≤ 1.5×upper normal limit exclusion criteria: 1. the evidence of relapse of distant metastasis 2. receiving treatment of other anti-cancer drug or methods 3. patients have low compliance and are not able to complete the entire trial 4. presence of uncontrolled life-threatening diseases 5. ct4 with infiltration of anterior organ on pretreatment mri 6. ct4 with infiltration of internal or external anal sphincter on pretreatment mri
a study to investigate efficacy and safety of weekly peg-somatropin (gensci004) in treatment naive children with growth hormone deficiency

Conditions: GHD

Summary: the purpose of this study is to evaluate the efficacy and safety of weekly gensci004 compared with daily genotropin in treatment-naive children with growth failure due to ghd.

the purpose of this phase 3 study is to evaluate the efficacy, safety, and tolerability of weekly gensci004 compared to daily genotropin over 52 weeks in prepubertal treatment-naïve children with growth failure due to ghd.

Eligibility criteria:
inclusion criteria: 1. prepubertal children with ghd in tanner stage 1 2. baseline ht at least -2.0 sd below the mean ht for ca and sex (ht sds ≤ 2.0). 3. body mass index (bmi) within ±2.0 sd of the mean bmi for ba and sex. 4. growth hormone stimulation tests: ≤10 ng/ml 5. baseline igf 1 level of at least 1.0 sd below the mean igf 1 level standardized for age and sex (igf 1 sds ≤-1.0) 6. normal 46 xx karyotype for girls. 7. children with multiple hormonal deficiencies must be on stable replacement therapy for other hypothalamo-pituitary axes for at least 3 months 8. written, signed informed consent of the parent(s) or legal guardian(s) of the participant and written assent of the participant exclusion criteria: 1. ba≥ca 2. prior exposure to rhgh, long-acting growth hormones, or igf 1 therapy. 3. major medical conditions or presence of contraindication to human growth hormone (hgh) treatment 4. participation in any other trial of an investigational agent within 3 months prior to screening. 5. any reason per investigator's discretion

Keywords: ghd growth hormone deficiency
impact of video discharge instructions on heart failure patient's knowledge

Conditions: Heart Failure

Summary: with improve care of patients with heart failure, many patients are living longer. care for these patients is now not only focused on mortality but also on the quality of life. patient knowledge about heart failure and their overall compliance with the necessary lifestyle changes will lead to an improved quality of life. discovering alternative ways to improve patient knowledge is key to long term survival. this studies objective is to assess the overall impact of video discharge instructions as compared to paper discharge instructions on heart failure knowledge among an under-served patient population.

in this study, we will randomized patients admitted to the hospital with heart failure exacerbation to receive either paper or video discharge instructions within a day prior to discharge. the video and paper instructions will have the same content. the patients will take a pre-test and post-test and the change in scores among the patients who received the video and paper discharge instructions will be compared. other points of interest include participant satisfactions with discharge instruction, followup at post hospital appointment and 30-day readmission. data to be collected includes: 1. medial history of the patient 2. educational background 3. social status 4. patients health measurement: self efficacy for managing medications and treatment management, informational support

Eligibility criteria:
inclusion criteria: * hospital admission with a diagnosis of heart failure (hf)- heart failure with reduced ejection fraction or heart failure with preserved ejection fraction * planned discharge from hospital to home setting * able to read and write english * acceptable to answer questionnaire and to receive a call at the end of the study exclusion criteria: * planned discharge to long term acute care * patients with unstable housing * imprisoned patients * patients who are pregnant * illiteracy (defined as inability to write or read) and non-native speakers of english * impaired cognition * impaired vision * patients with end stage renal disease(esrd) * cancer patients

Keywords: patient knowledge heart failure self care